Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Boston Scientific (BSX) one of those stocks right now? A quick glance at the ...

Learn more about whether Boston Scientific Corporation or Penumbra, Inc. is a better investment based on AAII's A+ Investor ...

Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.

Canaccord Genuity maintained its Buy rating on Boston Scientific (NYSE:BSX) shares and increased the price target to $117 from $101. The adjustment follows the company's robust fourth-quarter earnings ...

Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

Boston Scientific’s BSX robust expansion of operations ... The renowned manufacturer of medical devices and products has a market capitalization of $131.64 billion. BSX beat on earnings in ...

Boston Scientific (BSX) closed the most recent trading ... As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 2.1. The Medical - Products industry ...

Continuing its acquisition streak into 2025, Marlborough-based medical device manufacturer Boston Scientific has entered into a definitive agreement to acquire California-based medical equipment ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Boston Scientific has gained 3% since the start of the year compared to the -4.4% move for the Zacks Medical sector and the 10.2% return for the Zacks Medical - Products industry. The stock has a ...